WallStSmart
IMVT

Immunovant Inc

NASDAQ: IMVT · HEALTHCARE · BIOTECHNOLOGY

$29.06
-4.78% today

Updated 2026-06-05

Market cap
$6.90B
P/E ratio
P/S ratio
EPS (TTM)
$-2.77
Dividend yield
52W range
$14 – $36
Volume
1.9M

WallStSmart proprietary scores

23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
7.5
Quality
B+
3.0
Profitability
D
5.0
Valuation
C+
2/9
Piotroski F-Score
Weak
1.6
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target
$45.76
+57.47%
12-Month target
Intrinsic (DCF)
Margin of safety
2 Strong Buy11 Buy5 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 1.64 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-95.07M

Key financials

Revenue Net Income Free Cash Flow
Metric2023202420252026TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-210.96M$-259.34M$-413.84M$-505.61M$-147.86M
EPS$-2.77
Free cash flow$-188.39M$-214.59M$-376.63M$-407.32M$-95.07M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
IMVT$6.90B234.33.05.07.5Avoid
LLY$1.01T7610.010.04.36.0Strong Buy
JNJ$567.28B574.79.03.36.0-67.79%Buy
ABBV$391.50B634.08.04.05.0-48.06%Buy
UNH$373.28B545.35.54.05.5-24.80%Buy
NVS$289.19B493.39.03.34.5-62.62%Hold

Smart narrative

Immunovant Inc trades at $29.06. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.64, it sits in the distress.

Frequently asked questions

What is Immunovant Inc's stock price?

Immunovant Inc (IMVT) trades at $29.06.

Is Immunovant Inc overvalued?

Immunovant Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Immunovant Inc (IMVT)?

The 12-month analyst consensus target is $45.76, about 57.5% above the current $29.06. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Immunovant Inc's Altman Z-Score is 1.64, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE-59.30%
Beta0.79
50D MA$29.17
200D MA$24.34
Shares out0.21B
Float0.08B
Short ratio
Avg volume1.9M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years